[New therapies for rheumatoid arthritis]

Area of Science:

• Rheumatology and Immunology
• Pharmacology and Therapeutics

Background:

• Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease causing synovial membrane inflammation and joint destruction.
• Understanding RA pathogenesis has revealed novel therapeutic targets, including tumor necrosis factor (TNF), interleukins (IL-1, IL-6), and the JAK/STAT pathway.

Purpose of the Study:

• To review current therapeutic strategies for rheumatoid arthritis.
• To highlight the efficacy and targets of novel biologic and targeted synthetic therapies.

Main Methods:

• Review of approved therapies for rheumatoid arthritis.
• Discussion of biologic agents targeting TNF, IL-6, B cells, and T cells.
• Inclusion of data on the first approved Janus kinase (JAK) inhibitor.

Main Results:

• Five TNF antagonists are currently approved for RA treatment.
• Tocilizumab (IL-6 inhibitor) is effective as monotherapy.
• Rituximab and abatacept target B and T cells, respectively.
• Tofacitinib is the first approved kinase inhibitor for RA.
• Biologic drugs, often with methotrexate, demonstrate efficacy and can halt radiographic progression.

Conclusions:

• Advances in understanding RA pathogenesis have led to targeted therapies with proven efficacy.
• Biologics and targeted synthetic drugs offer significant benefits, including halting radiographic progression.
• Close monitoring for infections is crucial when managing patients on these advanced therapies.